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Fetal Exposure to Lisinopril: Neonatal Manifestations 
and Management 
Varsha Bhatt-Mehta, Pharm.D., and Karl S. Deluga, M.D. 
The use of angiotensin-converting enzyme (ACE) inhibitors in pregnancy has 
been associated with neonatal morbidity and mortality. The mechanism of renal 
dysfunction likely is related to fetal hypotension and prolonged decreased 
glomerular filtration. Six of 14 previously published cases of neonatal renal 
failure after maternal ACE inhibitor therapy resulted in death. Eight infants 
survived after peritoneal dialysis, some with residual renal impairment. Serum 
lisinopril levels and ACE activity in our patient indicate that during the anuric 
state the drug has an extremely prolonged half-life, and that it is removed by 
peritoneal dialysis. In view of this prolonged half-life and the drug’s continued 
suppression of ACE activity and renal function, we recommend institution of 
early dialysis in infants with renal failure after maternal therapy with lisinopril. 
(Pharmacotherapy 1993;13(5):515-518) 
Angiotensin-converting enzyme (ACE) inhibitors 
are commonly used in the treatment of essential 
and renovascular hypertension. Although not 
recommended, they are sometimes used in 
pregnant women to treat severe hypertension 
particularly when the risk of maternal morbidity is 
high. Numerous cases of neonatal morbidity and 
mortality have been reported in offspring of women 
who received these drugs during pregnancy. Both 
fatal anuria and reversible acute renal failure have 
been reported in infants exposed to enalapril or 
captopril in utero.’-ll 
Although ACE inhibitors are not thought to be 
teratogenic in animals, the frequency of stillbirths 
is increased in pregnant animals exposed to 
l 3  Little information is available about the 
use of lisinopril in pregnancy. We cared for a 
premature infant with chronic renal failure who was 
exposed to lisinopril in utero throughout pregnancy. 
The teratologic aspects of this case were reported 
previo~sly.~ 
Case Report 
A 1.48-kg boy was born to an 18-year-old 
woman at 33 weeks’ gestation by cesarean section 
due to premature onset of labor and breech 
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presentation. The pregnancy was complicated by 
long-standing maternal hypertension treated with 
lisinopril (Zestril) 10 mg/day. The infant’s Apgar 
scores were 4 and 7 at 1 and 5 minutes, 
respectively. He required mechanical ventilatory 
support and had a course consistent with 
moderate respiratory distress syndrome (RDS). Iri 
addition to prematurity, the physical examination 
was remarkable for a markedly hypoplastic skull. 
Throughout the first 8 days of life the baby 
remained anuric despite several fluid boluses and 
furosemide administration. Dopamine was started 
for hypotension. On day 9 of life the infant was 
transferred to the University of Michigan for further 
evaluation and treatment. At the time of transfer, 
his blood urea nitrogen was 27 mg/dl (9.64 
mmol/L) and serum creatinine was 7.0 mg/dl (619 
pmol/L). 
Further evaluation included renal ultrasonog- 
raphy, which showed normal renal architecture and 
size, and documented blood flow to both kidneys 
by Doppler examination. The femoral arteries 
were patent. Echocardiogram revealed a small 
patent ductus arteriosus. Cranial ultrasound was 
normal. The infant was diagnosed as having acute 
renal failure due to in utero exposure to an ACE 
inhibitor. This diagnosis was supported by 
hypoplasia of the skull, which has been associated 
with ACE  inhibitor^.^^ 5 9, I4 
Peritoneal dialysis was begun on day 9 of life. 
Due to technical problems, it was unsuccessful 
until day 10. The first urine output was on day 12 
at 0.23 ml/kg/hour and slowly increased over the 
next 10 days. 
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Table 1. Clinical and Laboratory Changes During Peritoneal Dialysis 
Lisinopril 
Urine ACE P RA Serum Dialysate 
(days) (rnl/kg/hr) (nmol/rnl/min) (ng/ml/hr) (ng/ml) (ng/m 1) 
Age 
12 0.23 7.9 
0.32 7.4 - 6.3 3.3 
17 0.30 - - 2.1 16 
0.39 - - 0.6 21 
0.56 19.5 30 
1.3 22.0 19.2 37 
2.6 38 
45 1.24 - 1 .o 
- 7.0a - 
- 
- 
- - - 
- - 
- - 0.7b 
- - 
Continuous peritoneal dialysis began on day 12 of life. 
Normal ACE 20-50 nmol/ml/min, normal PRA 0.5-3.5 ngimllhr. 
"Lisinopril concentration before effective dialysis. 
bLisinopril concentration before administration of enalapril. 
Initially, ACE activity was low (Table 1) and 
increased over the next 3 weeks as serum lisinopril 
concentrations decreased. After 4 weeks of 
dialysis plasma renin activity (PRA) was markedly 
elevated at 19.2 ng/ml/hour (normal range 0.5-3.5 
ng/ml/hr) and the serum lisinopril concentration 
was negligible (0.7 ng/ml). The infant was very 
hypertensive during this time. His clinical response 
to hydralazine and propranolol to control 
hypertension was minimal, and prolonged use of 
nitroprusside was required. At this time it was 
decided to administer an ACE inhibitor based on 
the hypothesis that there may have been 
hyperplasia of the juxtaglomerular apparatus 
producing the high renin activity.6 No further drug 
levels were measured after this time. 
The infant responded well to enalapril 0.04 
mg/kg every 6 hours intravenously. Four days later 
his renin value dropped to 1.0 ng/ml/hour. His 
blood pressure was controlled, and his urine output 
at this time was approximately 1.3 ml/kg/hour. 
At 11 weeks, an open renal biopsy showed 
extensive atrophy and loss of tubules associated 
with interstitial fibrosis. Some tubules were dilated 
with cellular debris. The brush border of the 
proximal tubular epithelium did not stain with para- 
aminosalicylic acid (PAS). The extensive tubular 
atrophy and interstitial fibrosis was interpreted to 
be a result of previous tubular injury and interstitial 
nephritis possibly secondary to a nephrotoxic 
agent. No hypertrophy of the juxtaglomerular 
apparatus was seen. 
Adequate renal function did not return. The 
infant was discharged from the hospital at 10 
months of age on continuous peritoneal dialysis for 
severe renal failure. He received a renal transplant 
at approximately 22 months that is functioning well. 
He appears cognitively normal, but has suffered 
from malabsorption and severe failure to thrive, 
and remains small for his age. 
Discussion 
This case illustrates neonatal anuria due to in 
utero exposure to lisinopril, a newer ACE inhibitor. 
Numerous reports of fetal and neonatal morbidity 
and mortality after the use of these drugs during 
pregnancy can be found in the There 
are also reports of pregnant women receiving ACE 
inhibitors with no obvious ill effects on pregnancy 
outcome,l1, 15, l 6  suggesting that several factors 
such as the timing or duration of exposure, 
particularly during the second and third trimesters, 
may be crucial. Consequently, the frequency of 
fetal exposure and the likelihood of subsequent 
neonatal morbidity is unknown, but both are 
undoubtedly underreported in the literature. 
Pregnancies without untoward neonatal events 
would be less likely to be reported, and very 
premature infants who die soon after birth with 
RDS, refractory hypotension, and short-term anuria 
are not likely to be recognized as suffering from the 
effects of fetal ACE inhibitor exposure. In addition, 
the relative risks of neonatal renal failure after 
exposure to different ACE inhibitors are unknown. 
The typical characteristics of fetal exposure 
reported with captopril and enalapril include renal 
dysfunction with severe oliguria or anuria in the 
absence of a history suggestive of asphyxia at 
birth,'-'l normal-size kidneys without hydro- 
n e p h r ~ s i s , ~ - ~ ,  variable but often intractable 
h y pote ns i o n , 1 ,  3-5, 7-9 and osseous cranial 
h y p o p l a ~ i a . ~ ,  5, 8, 9, l 4  Patent ductus arteriosus 
and/or pulmonary hypoplasia also were present in 
many of the patients, but they are commonly 
related to prematurity or oligohydramnios and are 
thus not easily attributable to exposure to ACE 
inhibitors. Features seen in our patient were 
severe renal failure at birth without antecedent 
asphyxia, normal-size kidneys, hypotension, and 
cranial hypoplasia. 
Possible mechanisms by which the agents might 
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cause renal injury are speculative. Data from 
animal studies indicate that glomerular filtration is 
controlled, at least partially, through the renin- 
angiotensin system. Blockage of angiotensin II in 
dogs during renal artery hypotension results in a 
marked decrease in glomerular filtration rate (GFR) 
and filtration fraction despite well-maintained renal 
blood f10w.I~ This mechanism is thought to be 
involved in the transient renal impairment observed 
in humans with renal artery stenosis during 
treatment with captopril.I8 A similar mechanism 
may be operative in fetuses exposed to the agents. 
The combination of fetal hypoten~ion’~ and loss of 
a functional renin-angiotensin system results in a 
marked fall in GFR.” Over a prolonged period, the 
lack of GFR would likely impair renal tubular 
development. The findings in our patient with 
extreme paucity of tubules are consistent with this 
mechanism, as are the simultaneous changes in 
urine output as ACE activity increased. 
Calvarial hypoplasia, a very uncommon 
congenital abnormality that has been reported in 
connection with fetal exposure to ACE  inhibitor^,^, 5, 
8 , 9 , 1 4  is also postulated to be related to fetal 
hypotension. Decreased fetal blood pressure 
associated with increased uterine pressure directly 
on the developing bones of the skull due to 
prolonged oligohydramnios may impair cranial 
ossifi~ation.~ 
Treatment of neonates with renal failure at birth 
after in utero exposure to ACE inhibitors has been 
varied. Although many of the infants were 
premature and suffered from other problems likely 
to complicate the clinical course, the presence of 
anuria was an ominous finding. Despite dialysis, 
deaths occurred due to persistent renal failure, 
although survivors had eventual return of variable 
degrees of renal function.’-” 
Continued suppression of ACE activity and 
elevation of plasma renin activity were documented 
3 days after birth in a newborn whose mother took 
enalapri1.6 The ACE activity increased and 
enalapril plasma concentrations decreased with 1 
week of dialysis. In our patient, serum lisinopril 
concentration 12 days after birth, prior to the onset 
of effective dialysis, was 7.0 ng/ml and ACE 
activity was suppressed at 7.9 nmol/ml/minute, 
indicating minimal or no excretion of the drug over 
a prolonged period. This is consistent with 
lisinopril not undergoing any measurable 
metabolism.20 In this infant, it was effectively 
removed by peritoneal dialysis, as shown by its 
decreasing serum levels and its presence in the 
dialysate. It is likely that hemodialysis would be 
more effective in removing circulating ACE inhibitor 
in the face of hypotension; however, the attendant 
risks involved with hemodialysis, including rapid 
fluid shifts and the need for systemic heparin 
therapy, especially when the patient is a premature 
infant at risk of intraventricular hemorrhage, must 
also be considered. 
Lisinopril is a water-soluble, small-molecular- 
weight compound (mw 441 5 3  daltons). The peak 
serum concentration of a single dose is linearly 
related to the amount given. About 30% of the 
drug is recovered unchanged from urine and about 
70% appears in feces. There appears to be no 
metabolism and no binding to serum proteins other 
than ACE. The half-life of the drug in adults is 
12-1 3 hours.20 
The peak serum concentration of lisinopril after a 
10-mg dose is about 42 ng/ml.21 In our patient, the 
mother received 10 mg/day throughout pregnancy, 
providing a steady-state concentration probably 
less than 42 ng/ml, assuming the usual increase in 
glomerular filtration that occurs with pregnancy. 
The initial serum concentration of lisinopril in the 
neonate was 7 ng/ml before dialysis was started. 
Since there was no urine or stool output before this 
time, it appears that fetal levels are approximately 
20% of maternal levels. 
Lisinopril has a very large volume of distribution 
124 f 16 L,20 and hence serum concentrations may 
not be a true reflection of the amount of drug in the 
body. Examination of the concentrations in serum 
and dialysate revealed a substantial amount was 
removed by dialysis. The infant was not fed during 
the first 4 weeks of life and had two meconium 
stools and minimal urine output during this time, 
indicating that most of the drug was removed by 
dialysis. 
Recent changes in package insert labeling, 
stating “when used in pregnancy during the second 
and third trimesters, ACE inhibitors can cause 
injury and even death to the developing fetus” 
strongly discourage the drugs’ use during 
pregnancy. However, through ignorance or the 
need to treat severe refractory hypertension, they 
will occasionally be given to pregnant women 
despite extreme risk to the fetus and neonate. 
Health care providers must be aware of the 
potential problems in the newborn after exposure. 
In infants with severe oliguria or anuria, the 
prolonged serum half-life of lisinopril and other 
drugs of this class may prolong renal failure and 
hypotension. In such circumstances we believe 
immediate hemodialysis or peritoneal dialysis is 
indicated. 
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